EUCTR2012-002630-36-Outside-EU/EEA进行中（未招募）不适用
A PHASE I/II, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF ETRAVIRINE (ETR) IN ANTIRETROVIRAL (ARV) TREATMENT-EXPERIENCED HIV-1 INFECTED INFANTS AND CHILDREN, AGED = 2 MONTHS TO < 6 YEARS
The National Institute of Allergy and Infectious Diseases (NIAID)0 个研究点目标入组 50 人开始时间: 2014年2月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- A confirmed HIV-1 infection
- •- Age = 2 months to < 6 years old at study entry.
- •- HIV-1 RNA viral load > 1000 copies/mL (within the previous 90 days prior to screening) AND an HIV-1 RNA viral load > 1000 copies/mL at screening.
- •- Treatment experienced children on a failing combination antiretroviral regimen (containing at least 3 ARVs) for at least 8 weeks
- •Treatment experienced children on a treatment interruption of at least 4 weeks with a history of virologic failure while on a combination antiretroviral regimen (containing at least 3 ARVs)
- •- Parent or legal guardian able and willing to provide signed informed consent and to have the subject followed at the clinic site
- •- Availability of sufficient active ARV drugs to create an OBR consistent with protocol requirements
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Evidence of phenotypic resistance to ETR at screening. Phenotypic cutoffs of >10 for loss of sensitivity for cohorts I, II and III.
- •- Known history of HIV-2 infection in subject or subject’s mother.
- •- Diagnosis of a new CDC Stage C (per 1994 Revised Classification System for Human Immunodeficiency Virus Infection in Children Less than 13 Years of Age) criteria or opportunistic or bacterial infection diagnosed within 30 days prior to screening and not considered clinically stable.
- •- Prior history of malignancy.
- •- Any clinically significant diseases (other than HIV infection) or clinically significant findings during the screening medical history or physical examination that, in the investigator’s opinion, would place the subject at an unacceptable risk of injury; render the subject unable to meet the requirements of the protocol; compromise the outcome of this study; or lead to the child being ineligible for participation.
- •- Current = Grade 3 of any of the following laboratory toxicities at screening: neutrophil count, hemoglobin, platelets, AST, ALT, lipase, serum creatinine.
- •- Current or anticipated use of any disallowed medications.
- •- Subject’s family is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate to a non-IMPAACT study site during the study.
- •- History of non-adherence with ARV medications that in the investigator’s opinion could affect the ability of the subject to comply with the protocol/procedures.
- •- Grade 3 or higher QTc or PR interval prolongation from the ECG at screening.
研究者
相似试验
进行中（未招募）
不适用
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of AgeHIV-1 InfectionMedDRA version: 16.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2011-001680-44-Outside-EU/EEAThe National Institute of Allergy and Infectious Diseases (NIAID)60
招募中
不适用
The Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin LymphomaB-cell Non-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma cancer10025320NL-OMON54276Genmab50
招募中
不适用
A Phase 1b/2a, Open Label Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104IAR in Adults with Eosinophilic Esophagitis (RESOLVE)Digestive system disorderSwelling of esophagus10017969NL-OMON56323Eupraxia Pharmaceuticals Inc.6
未知
1 期
A Phase 1, 2, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinomanresectable Locally Advanced or Metastatic, Medullary Thyroid CarcinomaJPRN-jRCT2080221951AstraZeneca
已完成
1 期
A Study of Lazertinib as Monotherapy or in Combination with Amivantamab in Participants with Advanced Non-small Cell Lung CancerJPRN-jRCT2080224850Janssen Pharmaceutical K.K.520